New vaccines for neglected parasitic diseases and dengue

Translational Research

Volumn 162, Issue 3, 2013, Pages 144-155

  Beaumier, Coreen M ^a   Gillespie, Portia M ^a   Hotez, Peter J ^a   Bottazzi, Maria Elena ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; ANTIPARASITIC AGENT; ANTITRYPANOSOMAL AGENT; CHIMERIC LIVE ATTENUATED DENGUE VACCINE; DENGUE VACCINE; DNA VACCINE; E 6020; HOOKWORM VACCINE; INACTIVATED VIRUS VACCINE; LEISHMANIA VACCINE; LIVE ATTENUATED DENGUE VACCINE; LIVE VACCINE; MEBENDAZOLE; ONCHOCERCA VACCINE; ORAL POLIOMYELITIS VACCINE; PRAZIQUANTEL; PURIFIED INACTIVATED DENGUE VACCINE; RECOMBINANT E PROTEIN VACCINE; RECOMBINANT NECATOR AMERICANUS GLUTATHIONE S TRANSFERASE 1 VACCINE; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; SCHISTOSOMA MANSONI TETRASPANIN PROTEIN 2 VACCINE; SCHISTOSOMA VACCINE; TETRAVAX DV; UNCLASSIFIED DRUG; VACCINE; WEST NILE VACCINE; YFV 17D;

AEDES ALBOPICTUS; AMEBIASIS; CHAGAS DISEASE; CLINICAL TRIAL (TOPIC); DENGUE; DENGUE VIRUS; DISABILITY; DRUG EFFICACY; FASCIOLIASIS; HEPATITIS B VIRUS; HOOKWORM INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNITY; LEISHMANIASIS; MALARIA; NECATOR AMERICANUS; NEGLECTED TROPICAL DISEASE; NONHUMAN; ONCHOCERCIASIS; PARAGONIMIASIS; PRIORITY JOURNAL; REINFECTION; REVIEW; SCHISTOSOMA HEMATOBIUM; SCHISTOSOMA INTERCALATUM; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SKIN LEISHMANIASIS; TRICHURIASIS; TROPICAL DISEASE;

EID: 84882785758     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2013.03.006     Document Type: Review

References (65)

1. AVERT. Global HIV and AIDS estimates, 2009 and 2010. Available at: http://www.avert.org/worldstats.htm. Accessed November 4, 2012.
2. World Health Organization. Tuberculosis fact sheet 2012. Available at: http://www.who.int/mediacentre/factsheets/fs104/en/. Accessed November 4, 2012.
3. P.J. Hotez The Four Horsemen of the Apocalypse: tropical medicine in the fight against plague, death, famine, and war Am J Trop Med Hyg 87 2012 3 10
4. A fall to cheer. The Economist 2012. Available at: http://www.economist. com/node/21548963. Accessed November 4, 2012.
5. P.J. Hotez, J.M. Bethony, S.C. Oliveira, P.J. Brindley, and A. Loukas Multivalent anthelminthic vaccine to prevent hookworm and schistosomiasis Expert Rev Vaccines 7 2008 745 752
6. P.J. Hotez, A. Fenwick, L. Savioli, and D.H. Molyneux Rescuing the bottom billion through control of neglected tropical diseases Lancet 373 2009 1570 1575
7. P.J. Hotez Empowering women and improving female reproductive health through control of neglected tropical diseases PLoS Negl Trop Dis 3 2009 e559
8. P.S. Mbabazi, O. Andan, D.W. Fitzgerald, L. Chitsulo, D. Engels, and J.A. Downs Examining the relationship between urogenital schistosomiasis and HIV infection PLoS Negl Trop Dis 5 2011 e1396
9. World Health Organization. Neglected tropical diseases. 2012. Available at: http://www.who.int/gho/neglected-diseases/en/index.html. Accessed November 4, 2012.
10. P. Hotez A handful of 'antipoverty' vaccines exist for neglected diseases, but the world's poorest billion people need more Health Aff 30 2011 1080 1087
11. D.J. Gubler Aedes aegypti and Aedes aegypti-borne disease control in the 1990s: top down or bottom up: Charles Franklin Craig lecture Am J Trop Med Hyg 40 1989 571 578
12. S. Kalayanarooj, D.W. Vaughn, and S. Nimmannitya Early clinical and laboratory indicators of acute dengue illness J Infect Dis 176 1997 313 321
13. M.G. Guzman, and G. Kouri Dengue: an update Lancet Infect Dis 2 2002 33 42
14. Centers for Disease Control and Prevention Locally acquired dengue: Key West, Florida, 2009-2010 MMWR Morb Mortal Wkly Rep 59 2010 577 581
15. S.B. Halstead Immune enhancement of viral infection Prog Allergy 31 1982 301 364
16. N. Sangkawibha, S. Rojanasuphot, and S. Ahandrik Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand: I. The 1980 outbreak Am J Epidemiol 120 1984 653 669
17. S.B. Halstead, S. Nimmannitya, C. Yamarat, and P.K. Russell Hemorrhagic fever in Thailand; recent knowledge regarding etiology Jpn J Med Sci Biol 20 1967 96 103
18. S.C. Kliks, S. Nimmanitya, A. Nisalak, and D.S. Burke Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants Am J Trop Med Hyg 38 1988 411 419
19. S.C. Kliks, A. Nisalak, W.E. Brandt, L. Wahl, and D.S. Burke Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever Am J Trop Med Hyg 40 1989 444 451
20. I. Kurane, B.L. Innis, and A. Nisalak Human T cell responses to dengue virus antigens: proliferative responses and interferon gamma production J Clin Invest 83 1989 506 513
21. I. Kurane, A. Meager, and F.A. Ennis Dengue virus-specific human T cell clones: serotype cross-reactive proliferation, interferon gamma production, and cytotoxic activity J Exp Med 170 1989 763 775
22. A. Mathew, I. Kurane, and S. Green Predominance of HLA-restricted cytotoxic T-lymphocyte responses to serotype-cross-reactive epitopes on nonstructural proteins following natural secondary dengue virus infection J Virol 72 1998 3999 4004
23. J. Mongkolsapaya, W. Dejnirattisai, and X.N. Xu Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever Nat Med 9 2003 921 927
24. National Institute of Allergy and Infectious Diseases. Evaluating the safety and immune response to two admixtures of a tetravalent dengue virus vaccine. 2012. Available at: http://clinicaltrials.gov/ct2/show/NCT01506570? term=Tetravax-DV&rank=3. Accessed November 4, 2012.
25. S.J. Thomas, and T.P. Endy Vaccines for the prevention of dengue: development update Hum Vaccin 7 2011 674 684
26. Sanofi-Pasteur. Sanofi Pasteur's dengue vaccine demonstrates proof of efficacy. 2012. Available at: 5 www.sanofipasteur.com/articles/1118-sanofi- pasteur's-dengue-vaccine-demonstrates-proof-of-efficacy.html. Accessed November 2, 2012.
27. Inviragen. Safety and immunogenicity study to assess DENVax, a live attenuated tetravalent vaccine for prevention of dengue fever. 2011. Available at: http://clinicaltrials.gov/ct2/show/NCT01224639?term=DENVax&rank=1. Accessed November 14, 2012.
28. U.S. Army Medical Research and Materiel Command. A two-dose primary vaccination study of a tetravalent dengue virus purified inactivated vaccine vs. placebo in healthy adults. 2012. Available at: http://clinicaltrials.gov/ct2/ show/NCT01666652?term=dengue+PIV&rank=3. Accessed November 14, 2012.
29. U.S. Army Medical Research and Materiel Command. A two-dose primary vaccination study of a tetravalent dengue virus purified inactivated vaccine vs. placebo in healthy adults (in Puerto Rico) (DPIV-002). 2012. Available at: http://clinicaltrials.gov/ct2/show/NCT01702857?term=dengue+PIV&rank=1. Accessed November 14, 2012.
30. U.S. Army Medical Research and Materiel Command. Safety study of a vaccine (DENV-1 PIV) to prevent dengue disease. 2012. Available at: http://clinicaltrials.gov/ct2/show/NCT01502735?term=dengue+PIV&rank=2. Accessed November 14, 2012.
31. Hawaii Biotech, Inc. Study of HBV-001 D1 in healthy adults. 2011. Available at: http://clinicaltrials.gov/ct2/show/NCT00936429?term=HBV- 001+D1&rank=1. Accessed November 14 2012.
32. U.S. Army Medical Research and Material Command. Evaluation of the safety and the ability of a DNA vaccine to protect against dengue disease. 2012. Available at: http://clinicaltrials.gov/ct2/show/NCT01502358?term= dengue+DNA+vaccine&rank=2. Accessed November 14, 2012.
33. P.J. Hotez, J.M. Bethony, D.J. Diemert, M. Pearson, and A. Loukas Developing vaccines to combat hookworm infection and intestinal schistosomiasis Nat Rev Microbiol 8 2010 814 826
34. R. Larocque, M. Casapia, E. Gotuzzo, and T.W. Gyorkos Relationship between intensity of soil-transmitted helminth infections and anemia during pregnancy Am J Trop Med Hyg 73 2005 783 789
35. R.J. Stoltzfus Iron deficiency: global prevalence and consequences Food Nutr Bull 24 2003 S99 103
36. S. Brooker, W. Akhwale, and R. Pullan Epidemiology of plasmodium-helminth co-infection in Africa: populations at risk, potential impact on anemia, and prospects for combining control Am J Trop Med Hyg 77 2007 88 98
37. J. Keiser, and J. Utzinger Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis JAMA 299 2008 1937 1948
38. M. Albonico, P.G. Smith, and E. Ercole Rate of reinfection with intestinal nematodes after treatment of children with mebendazole or albendazole in a highly endemic area Trans R Soc Trop Med Hyg 89 1995 538 541
39. P.D. Hotez, D. Diemert, Bacon, and K.M. Decade of vaccine collaboration (DoVC): Human Hookworm Vaccine Case Study Vaccine 31S 2013 B227 B232
40. A. Das, and N. Ali Vaccine development against Leishmania donovani Front Immunol 3 2012 99
41. M.S. Duthie, V.S. Raman, F.M. Piazza, and S.G. Reed The development and clinical evaluation of second-generation leishmaniasis vaccines Vaccine 30 2012 134 141
42. R. Nagill, and S. Kaur Vaccine candidates for leishmaniasis: a review Int Immunopharmacol 11 2011 1464 1488
43. S. Bertholet, Y. Goto, and L. Carter Optimized subunit vaccine protects against experimental leishmaniasis Vaccine 27 2009 7036 7045
44. J. Chakravarty, S. Kumar, and S. Trivedi A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis Vaccine 29 2011 3531 3537
45. R. Gomes, C. Teixeira, and F. Oliveira KSAC, a defined Leishmania antigen, plus adjuvant protects against the virulence of L. major transmitted by its natural vector Phlebotomus duboscqi PLoS Negl Trop Dis 6 2012 e1610
46. Infectious Disease Research Institute. Safety and immunogenicity of the LEISH-F2 + MPL-SE Vaccine with SSG for patients with PKDL. 2011. http://clinicaltrials.gov/show/NCT00982774. Accessed on November 14, 2012.
47. Infectious Disease Research Institute. A study of the efficacy and safety of the LEISH-F2 + MPL-SE vaccine for treatment of cutaneious leishmaniasis. 2012. http://clinicaltrials.gov/ct2/show/NCT01011309?term=nct01011309&rank= 1. Accessed November 14, 2012.
48. Infectious Disease Research Institute. Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers. 2012. Available at: http://clinicaltrials.gov/ct2/ show/NCT01484548?term=phase+I+LEISH- F3+vaccine+trial+in+healthy+adult+volunteers&rank=1. Accessed: November 14, 2012.
49. Sabin Vaccine Insitute. Schistosmiasis vaccine project status. 2012. Available at: http:www.sabin.org/programs/schistosomiasis-vaccine/project- status. Accessed November 14, 2012.
50. C.H. King Parasites and poverty: the case of schistosomiasis Acta Trop 113 2010 95 104
51. H.E. McWilliam, P. Driguez, D. Piedrafita, D.P. McManus, and E.N. Meeusen Novel immunomic technologies for schistosome vaccine development Parasite Immunol 34 2012 276 284
52. ClinicalTrials.gov N. Clinical trial of Bilhvax, a vaccine candidate against schistosomiasis (Bilhvax1a). Lille: University Hospital; 2012. Available at: http://clinicaltrials.gov/ct2/show/NCT01512277?term= clinical+trial+of+Bilhvax&rank=1. Accessed November 14, 2012.
53. G. Riveau, D. Deplanque, and F. Remoue Safety and immunogenicity of rSh28GST antigen in humans: phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis PLoS Negl Trop Dis 6 2012 e1704
54. Oswaldo Cruz Foundation. Study to evaluate the sa fety of the vaccine prepared sm14 against schistosomiasis. 2012. http://clinicaltrials.gov/ct2/show/ NCT01154049?term= study+to+evaluate+the+safety+of+the+vaccine+prepared+sm14+against&rank=1. Accessed November 14, 2012.
55. B.Y. Lee, K.M. Bacon, A.R. Wateska, M.E. Bottazzi, E. Dumonteil, and P.J. Hotez Modeling the economic value of a Chagas' disease therapeutic vaccine Hum Vaccin Immunother 8 2012 1 9
56. E. Dumonteil, M.E. Bottazzi, and B. Zhan Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects Expert Rev Vaccines 11 2012 1043 1055
57. I. Quijano-Hernandez, and E. Dumonteil Advances and challenges towards a vaccine against Chagas disease Hum Vaccin 7 2011 1184 1191
58. M.H. Collins, J.M. Craft, J.M. Bustamante, and R.L. Tarleton Oral exposure to Trypanosoma cruzi elicits a systemic CD8(+) T cell response and protection against heterotopic challenge Infect Immun 79 2011 3397 3406
59. M.P. Zago, A.B. Barrio, R.M. Cardozo, T. Duffy, A.G. Schijman, and M.A. Basombrio Impairment of infectivity and immunoprotective effect of a LYT1 null mutant of Trypanosoma cruzi Infect Immun 76 2008 443 451
60. S. Lustigman, J.H. McKerrow, and M.E. Bottazzi Vaccines linked to chemotherapy: a new approach to control helminth infections C.R. Caffrey, Parasitic helminths: targets, screens, drugs and vaccines 1st ed. 2012 Wiley-VCH Verlag Weinheim, Germany 357 369
61. T.B. Nutman Future directions for vaccine-related onchocerciasis research Trends Parasitol 18 2002 237 239
62. M. Lizotte-Waniewski, W. Tawe, and D.B. Guiliano Identification of potential vaccine and drug target candidates by expressed sequence tag analysis and immunoscreening of Onchocerca volvulus larval cDNA libraries Infect Immun 68 2000 3491 3501
63. J.A. Cook, C. Steel, and E.A. Ottesen Towards a vaccine for onchocerciasis Trends Parasitol 17 2001 555 558
64. M.H. Djingarey, R. Barry, and M. Bonkoungou Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience Vaccine 30 2012 B40 B45
65. F.M. Ndungu, J. Mwacharo, and D. Kimani A statistical interaction between circumsporozoite protein-specific T cell and antibody responses and risk of clinical malaria episodes following vaccination with RTS, S/AS01E PLoS One 7 2012